XXE5XM5* 	[measurement of infection, whole blood nucleic acid-base microbial detection, new technology group 5
X27H385*	dilation of right femoral artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27H395*	dilation of right femoral artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27H3B5*	dilation of right femoral artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27H3C5*	dilation of right femoral artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27J385*	dilation of left femoral artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27J395*	dilation of left femoral artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27J3B5*	dilation of left femoral artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27J3C5*	dilation of left femoral artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27K385*	dilation of proximal right popliteal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27K395*	dilation of proximal right popliteal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27K3B5*	dilation of proximal right popliteal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27K3C5*	dilation of proximal right popliteal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27L385*	dilation of proximal left popliteal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27L395*	dilation of proximal left popliteal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27L3B5*	dilation of proximal left popliteal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27L3C5*	dilation of proximal left popliteal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27M385*	dilation of distal right popliteal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27M395*	dilation of distal right popliteal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27M3B5*	dilation of distal right popliteal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27M3C5*	dilation of distal right popliteal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27N385*	dilation of distal left popliteal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27N395*	dilation of distal left popliteal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27N3B5*	dilation of distal left popliteal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27N3C5*	dilation of distal left popliteal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27P385*	dilation of right anterior tibial artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27P395*	dilation of right anterior tibial artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27P3B5*	dilation of right anterior tibial artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27P3C5*	dilation of right anterior tibial artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27Q385*	dilation of left anterior tibial artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27Q395*	dilation of left anterior tibial artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27Q3B5*	dilation of left anterior tibial artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27Q3C5*	dilation of left anterior tibial artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27R385*	dilation of right posterior tibial artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27R395*	dilation of right posterior tibial artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27R3B5*	dilation of right posterior tibial artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27R3C5*	dilation of right posterior tibial artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27S385*	dilation of left posterior tibial artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27S395*	dilation of left posterior tibial artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27S3B5*	dilation of left posterior tibial artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27S3C5*	dilation of left posterior tibial artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27T385*	dilation of right peroneal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27T395*	dilation of right peroneal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27T3B5*	dilation of right peroneal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27T3C5*	dilation of right peroneal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27U385*	dilation of left peroneal artery with sustained release drug eluting intraluminal device {percutaneous} approach, new technology group 5	
X27U395*	dilation of left peroneal artery with two sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27U3B5*	dilation of left peroneal artery with three sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X27U3C5*	dilation of left peroneal artery with four or more sustained release drug eluting intraluminal devices {percutaneous} approach, new technology group 5	
X2A5312   [cerebral embolic filtration] & [innominate artery] & [common carotid artery]
X2A6325   [cerebral embolic filtration] `aortic arch`
X2AH336	  [cerebral embolic filtration] {extracorporeal flow reversal circuit} `right common carotid artery` & [percutaneous] 
X2AJ336	  [cerebral embolic filtration] {extracorporeal flow reversal circuit} `left common carotid artery` & [percutaneous] 
X2C0361   [extirpation] `coronary artery` {orbital atherectomy} & [percutaneous]
X2C1361   [extirpation] `coronary artery` `coronary artery` {orbital atherectomy} & [percutaneous]
X2C2361   [extirpation] `coronary artery` `coronary artery` `coronary artery` {orbital atherectomy} & [percutaneous]
X2C3361   [extirpation] `coronary artery` `coronary artery` `coronary artery` `coronary artery` {orbital atherectomy} & [percutaneous]
X2RF032   [replacement] `aortic valve` {zooplastic tissue} {rapid deployment technique} & [open]
X2RF332   [replacement] `aortic valve` {zooplastic tissue} {rapid deployment technique} & [percutaneous]
X2RF432   [replacement] `aortic valve` {zooplastic tissue} {rapid deployment technique} & [percutaneous endoscopic]
XHRPXL2   [replacement] `skin` {skin substitute, porcine liver derived}
XK02303   [introduction] `muscle` {concentrated bone marrow aspirate} & [percutaneous]
XNS0032   [reposition] `lumbar vertebra` {magnetically controlled growth rod} & [open]
XNS0332   [reposition] `lumbar vertebra` {magnetically controlled growth rod} & [percutaneous]
XNS3032   [reposition] `cervical vertebra` {magnetically controlled growth rod} & [open]
XNS3332   [reposition] `cervical vertebra` {magnetically controlled growth rod} & [percutaneous]
XNS4032   [reposition] `thoracic vertebra` {magnetically controlled growth rod} & [open]
XNS4332   [reposition] `thoracic vertebra` {magnetically controlled growth rod} & [percutaneous]
XR2G021   [monitoring] {knee arthroplasty} {right}
XR2H021   [monitoring] {knee arthroplasty} {left}
XT25XE5   [monitoring] `kidney` {fluorescent pyrazin}
XNU0356	  [supplement] `lumbar vertebra` {mechanically expandable} {synthetic} & [percutaneous] 
XNU4356	  [supplement] `thoracic vertebra` {mechanically expandable} {synthetic} & [percutaneous] 
XV508A4   [destruction] `prostate` {robotic waterjet ablation} & [endoscopic]
XW013F5   [introduction] {other therapeutic substance new technology} & [percutaneous]
XW013H6	  [introcuction] {other new technology monoclonal antibody}
XW013K6	  [introcuction] {leronlimab monoclonal antibody}
XW013S6	  [introcuction] {covid-19 vaccine} {dose 1} `subcutaneous tissue`
XW013T6	  [introcuction] {covid-19 vaccine} {dose 2} `subcutaneous tissue`
XW013U6	  [introcuction] {covid-19 vaccine} {percutaneous} `subcutaneous tissue`
XW023S6	  [introcuction] {covid-19 vaccine} {dose 1} `muscle`
XW023T6	  [introcuction] {covid-19 vaccine} {dose 2} `muscle`
XW023U6	  [introcuction] {covid-19 vaccine} `muscle`
XW033E6	  [introcuction] {etesevimab monoclonal antibody} `peripheral vein` {percutaneous}
XW033F6	  [introcuction] {bamlanivimab monoclonal antibody} `peripheral vein` {percutaneous}
XW033G6	  [introcuction] {regn-cov2 monoclonal antibody} `peripheral vein` {percutaneous}
XW033H6	  [introcuction] {other new technology monoclonal antibody} `peripheral vein` {percutaneous}
XW033L6	  [introcuction] {cd24fc immunomodulator} `peripheral vein` {percutaneous}
XW043E6	  [introcuction] {etesevimab monoclonal antibody} `central vein` {percutaneous}
XW043F6	  [introcuction] {bamlanivimab monoclonal antibody} `central vein` {percutaneous}
XW043G6	  [introcuction] {regn-cov2 monoclonal antibody} `central vein` {percutaneous}
XW043H6	  [introcuction] {other new technology monoclonal antibody} `central vein` {percutaneous}
XW043L6	  [introcuction] {cd24fc immunomodulator} `central vein` {percutaneous}
XW013W5   [introduction] {caplacizumab} `subcutaneous tissue`
XW033E5   [remdesivir] !{central vein} !{past status}
XW033F5   [introduction] {other therapeutic substance new technology} & ![central vein]
XW033G5   [sarilumab] & ![central vein]
XW033H5   [tocilizumab] & ![central vein]
XW033K5   [introduction] {fosfomycin anti infective} & ![central vein]	
XW033N5   [introduction] {meropenem vaborbactam anti infective} & ![central vein] 
XW033Q5   [introduction] {tagraxofusp erzs antineoplastic} & ![central vein] 
XW033S5   [introduction] {iobenguane i 131 antineoplastic} & ![central vein] 
XW033U5   [introduction] {imipenem cilastatin relebactam anti infective} & ![central vein]	
XW033W5   [introduction] {caplacizumab} & ![central vein]
XW043E5   [remdesivir] {central vein} !{past status}
XW043F5   [introduction] {other therapeutic substance new technology} & [central vein]
XW034G5   [sarilumab] & [central vein]
XW034H5   [tocilizumab] & [central vein] 	
XW043K5   [introduction] {fosfomycin anti infective} & [central vein] 
XW043N5   [introduction] {meropenem vaborbactam anti infective} & [central vein] 
XW043Q5   [introduction] {tagraxofusp erzs antineoplastic} & [central vein] 
XW043S5   [introduction] {iobenguane i 131 antineoplastic} & [central vein] 
XW043U5   [introduction] {imipenem cilastatin relebactam anti infective} & [central vein] 
XW043W5   [introduction] {caplacizumab} & [central vein]
XW0DXFS   [introcuction] {other therapeutic substance new technology} `mouth and pharynx`
XW0DXM6	  [baricitinib] `mouth and pharynx` !{natural opening}
XW0G7M6	  [introcuction] {baricitinib} `upper gi` {natural opening}
XW0H7M6	  [introcuction] {baricitinib} `lower gi` {natural opening}
XW0DXJ5   [introduction] {apalutamide antineoplastic} `mouth and pharynx` 
XW0DXL5   [introduction] {erdafitinib antineoplastic} `mouth and pharynx`
XW0DXR5   [introduction] {venetoclax antineoplastic} `mouth and pharynx`
XW0DXT5   [introduction] {ruxolitinib} `mouth and pharynx`
XW13325   [convalescent plasma] !{central vein} !{none}
XW14325	  [convalescent plasma] {central vein} !{none}
XW0DXV5   [introduction] {gilteritinib antineoplastic} `mouth and pharynx`
XXE5XM5   [measurement] {whole blood nucleic acid base microbial detection} 
XW03306   [introduction] {brexanolone} & ![central vein] 
XW03326   [introduction] {nerinitide} & ![central vein] 
XW03336   [introduction] {durvalumab antineoplastic} & ![central vein] 
XW03366   [introduction] {lefamulin anti-infective} & ![central vein] 
XW03396   [introduction] {ceftolozane/tzobactam anti-infective} & ![central vein] 
XW033A6   [introduction] {cefiderocol anti-infective} & ![central vein] 
XW033B6   [introduction] {omadacycline anti-infective} & ![central vein] 
XW033C6   [introduction] {eculizumab} & ![central vein] 
XW033D6   [introduction] {atezolizumab antineoplastic} & ![central vein] 
XW04306   [introduction] {brexanolone} & [central vein] 
XW04326   [introduction] {nerinitide} & [central vein] 
XW04336   [introduction] {durvalumab antineoplastic} & [central vein] 
XW04366   [introduction] {lefamulin anti-infective} & [central vein] 
XW04396   [introduction] {ceftolozane/tazobactam anti-infective} & [central vein] 
XW043A6   [introduction] {cefiderocol anti-infective} & [central vein] 
XW043B6   [introduction] {eculizumab} & [central vein] 
XW043D6   [introduction] {atezolizumab antineoplastic} & [central vein] 
XW097M5   [introduction] {esketamine hydrochloride} `nose` 
XW0DX66   [introduction] {lefamulin anti-infective} `mouth and pharynx` 
XW0G886   [introduction] {mineral-based topical hemostatic agent} `upper gi` & [endoscopic] 
XW0H886   [introduction] {mineral-based topical hemostatic agent} `lower gi` & [endoscopic] 
XW0Q316   [introduction] {eladocagene exuparvovec} `cranial cavity and brain` & [percutaneous] 
XW23346   [transfusion] {brexucabtagene autoleucel immunotherapy} & ![central vein] 
XW23376   [transfusion] {lisocabtagene mraleucel immunotherapy} & ![central vein] 
XW24346   [transfusion] {brexucabtagene autoleucel immunotherapy} & [central vein] 
XW24376   [transfusion] {lisocabtagene maraleucel immunotherapy} & [central vein] 
XXE5XN6   [measurement] {infection} {positive blood culture fluorescence hybridization organism Identification} {concentration and susceptibility} 
XXEBXQ6   [measurement] {Infection} {lower respiratory fluid nucleic acid-base microbial detection} 